Certain A Shares of Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-MAY-2022.
May 20, 2022
Share
Certain A Shares of Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-MAY-2022. These A Shares will be under lockup for 372 days starting from 14-MAY-2021 to 21-MAY-2022.
Details:
The companys holding shareholder, actual controller, Chairman Zhao Deyi, holding shareholder, actual controller, vice chairman Zhao Dezhong, Lianyungang Nuotai Investment Management Partnership Enterprise (Limited Partnership), Hangzhou Fulong Trading Co., Ltd., Hangzhou Pengting Trading Co., Ltd. promised that within 36 months after the listing date, will not transfer nor entrust to others for management direct or indirect shares in the company held prior to this issuance, nor allow the company to repurchase the said shares. If the closing price of the companys share is lower than the issue price for 20 consecutive trading days within 6 months after listing, or if the closing price of the companys share is lower than the issue price for the period ending six months after listing, then the lockup period will automatically be extended for 6 months.
Shareholders Jiande Wuxing Biotechnology Co., Ltd., Jiande Shangjiang Enterprise Management Co., Ltd.,Jiande Yuxin Enterprise Management Co., Ltd., Jiande Ruixin Enterprise Management Co., Ltd. promised that within 12 months after the listing date, will not transfer nor entrust to others for management direct or indirect shares in the company held prior to this issuance, nor allow the company to repurchase the said shares.
Directors, supervisors, management personnel, core technical personnel owning shares in the company, including Jin Fuqiang, Gu Haitao, Liu Biao, Directors, supervisors, management personnel holding shares in the company, including Pan Yuming, Ling Mingsheng, Pan Zhi, Sun Meilu, Xu Donghai, Guo Ting promised that within 12 months after the listing date, he or his close relatives will not transfer nor entrust to others for management direct or indirect shares in the company held prior to this issuance, nor allow the company to repurchase the said shares. If the closing price of the companys share is lower than the issue price for 20 consecutive trading days within 6 months after listing, or if the closing price of the companys share is lower than the issue price for the period ending six months after listing, then the lockup period will automatically be extended for 6 months.
Core technical personnel holding shares in the company, including Zhang Jianxing, Wang Wanqing, Zhao Chengqing, Zhu Weiying, Ding Jiansheng promised that within 12 months after the listing date and within 6 months after resignation, he or his close relatives will not transfer nor entrust to others for management direct or indirect shares in the company held prior to this issuance, nor allow the company to repurchase the said shares.
Jiande Nuoao Enterprise Management Partnership Enterprise (Limited Partnership), Jiande Taiao Enterprise Management Partnership Enterprise (Limited Partnership) promised that within 36 months after the listing date and within 6 months after resignation, he or his close relatives will not transfer nor entrust to others for management direct or indirect shares in the company held prior to this issuance, nor allow the company to repurchase the said shares.
Other shareholders promised not to transfer shares in the company within 1 year after listing date.
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd a China-based company principally engaged in the independent research and development and customized research and development and production of peptide drugs and small molecule drugs. The Company's main business includes customized product business and independently selected product business. Its customized product business includes CDMO (Contract Development and Manufacturing Organization) business, technical service CRO (Contract Research Organization) and transfer business. Its independently selected product business focuses on small molecule chemical drugs and conducts drug research and development in the key treatment areas of diabetes, cardiovascular diseases, tumors and other diseases. The Company mainly operates its businesses in the domestic market and overseas markets.